分组1 - ANI Pharmaceuticals reported quarterly earnings of $2.33 per share, exceeding the Zacks Consensus Estimate of $1.99 per share, and showing an increase from $1.63 per share a year ago, resulting in an earnings surprise of +17.32% [1] - The company achieved revenues of $247.06 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.04% and increasing from $190.57 million year-over-year [2] - ANI has consistently surpassed consensus EPS estimates for the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market with a decline of about 2.3% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $200.02 million, and for the current fiscal year, it is $8.22 on revenues of $1.07 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which ANI belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for ANI was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Alector reported a quarterly loss of $0.34 per share, surpassing the expected loss with a 13.71% earnings surprise.The company's revenue for the quarter was $6.24 million, significantly exceeding expectations by 103.43%.Alector's financial position is bolstered by $256 million in cash and equivalents, with a current ratio of 3.83, indicating a strong ability to cover short-term liabilities.Alector, Inc. (NASDAQ:ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenera ...

分组1 - Cytek Biosciences reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.02, compared to earnings of $0.07 per share a year ago, resulting in an earnings surprise of -166.67% [1] - The company posted revenues of $62.14 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.23%, and showing an increase from year-ago revenues of $57.48 million [2] - Cytek Biosciences shares have declined approximately 13.5% since the beginning of the year, while the S&P 500 has gained 1.5% [3] 分组2 - The earnings outlook for Cytek Biosciences is mixed, with the current consensus EPS estimate for the coming quarter at -$0.04 on revenues of $44.44 million, and -$0.02 on revenues of $207.38 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Cytek belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post a loss of $0.3 per share when it actually produced a loss of $0.15, delivering a surprise of +50%.Over the last four quarters, the compan ...

NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +46.01%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.42 per share when it actually produced a loss of $0.33, delivering a surprise of +21.43%.Over the last four quarters, the company ...

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.74%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.1, delivering a surprise of +600%.Over the last four quarters, the company has surpassed ...

Anika Therapeutics (ANIK) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,450.00%. A quarter ago, it was expected that this medical technology company would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of +100%.Over the last four ...

Core Viewpoint - Alkermes plc is a biopharmaceutical company focused on innovative medicines for central nervous system disorders and cancer, with a market capitalization of approximately $5.13 billion [1] Financial Performance - Alkermes reported a revenue decline of 10.6% for Q4 2025, totaling $384.55 million compared to the previous year [2] - Despite the revenue decline, Alkermes exceeded the Zacks Consensus Estimate of $379.96 million, resulting in a positive surprise of 1.21% [3] - The company reported earnings per share (EPS) of $0.46 for the quarter, surpassing the consensus estimate of $0.43, marking a 7.8% positive surprise, although down from $1.04 EPS in the same quarter last year [4] Stock Performance - The current stock price of ALKS is $31.04, reflecting a decrease of 7.04% or $2.35, with fluctuations between $30.54 and $32.78 during the trading day [5] - Over the past year, ALKS reached a high of $36.32 and a low of $25.17, with a trading volume of 3,898,927 shares indicating active investor interest [5] Analyst Outlook - Douglas Tsao from H.C. Wainwright set a price target of $43 for Alkermes, indicating a potential upside of 38.53% [2][6]

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.67%. A quarter ago, it was expected that this company would post a loss of $0.82 per share when it actually produced a loss of $0.34, delivering a surprise of +58.54%.Over the last four quarters, the compa ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.82%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.12, delivering a surprise of -25%.Over the last four quarters, the com ...